Engineered regulatory T cells targeting oxidized LDL cut plaque 70% in mice
Summarises a University of Pennsylvania preclinical study adapting CAR T therapy: Tregs engineered to recognise oxidized LDL dampened arterial inflammation and reduced plaque 70% in cholesterol-prone mice. Unlike cancer CAR-T, the cells suppress rather than destroy; it is a possible add-on for patients at risk despite cholesterol drugs.



